Advances and Challenges in KRAS Mutation Detection and Clinical Implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Aberrant RAS signaling pathway activation is a hallmark of many cancers, often driven by RAS gene mutations.
• Specific codon mutations in RAS genes significantly impact cancer patient outcomes.
• KRAS was historically considered undruggable, but novel inhibitors are emerging.

Purpose of the Study:

• To provide a comprehensive overview of KRAS mutation detection methods.
• To critically evaluate existing methods for accuracy, sensitivity, cost, and clinical applicability.
• To guide researchers and clinicians in selecting appropriate diagnostic tools.

Main Methods:

• Review of various KRAS mutation detection techniques, from research-use-only to in vitro diagnostics.
• Critical evaluation of published results based on key performance metrics.
• Analysis of suitability for different sample types and clinical settings.

Main Results:

• Numerous methods for KRAS mutation detection have been developed, aiming for robustness, speed, sensitivity, accuracy, and cost-effectiveness.
• These methods range from basic research tools to certified clinical diagnostic tests.
• Published data on method performance varies, necessitating careful evaluation.

Conclusions:

• Accurate KRAS mutation identification is essential for personalized cancer treatment strategies.
• The development of effective KRAS inhibitors highlights the importance of reliable detection methods.
• This review serves as a resource for understanding the landscape of KRAS mutation detection technologies.